Blood stem cell mobilization and collection in patients with lymphoproliferative diseases: Practical issues

European Journal of Haematology

Volumn 80, Issue 4, 2008, Pages 287-295

  Jantunen, Esa ^a   Kuittinen, Taru ^a  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Blood stem cell mobilization; Collection; Lymphoproliferative diseases; Mobilization failure

Indexed keywords

BLEOMYCIN; BORTEZOMIB; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUDARABINE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IFOSFAMIDE; MELPHALAN; METHYLPREDNISOLONE; MITOGUAZONE; OXALIPLATIN; PLERIXAFOR; PREDNISONE; PROCARBAZINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SARCOLYSIN; THALIDOMIDE; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

AMYLOIDOSIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BLOOD SAMPLING; CANCER COMBINATION CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG MEGADOSE; HODGKIN DISEASE; HUMAN; LOW DRUG DOSE; LYMPHOPROLIFERATIVE DISEASE; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; REVIEW; STEM CELL MOBILIZATION; T CELL LYMPHOMA;

HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; PATIENTS; SENSITIVITY AND SPECIFICITY;

EID: 40449141657     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2007.01026.x     Document Type: Review

References (74)

1. Gratwohl A, Baldomero H, Frauendorfer K, et al. Results of the EBMT activity survey 2005 on haematopoietic stem cell transplantation: focus on increasing use of unrelated donors. Bone Marrow Transplant 2007 39 : 71 87.
2. Russell NH, McQuaker G, Stainer C, et al. Stem cell mobilisation in lymphoproliferative diseases. Bone Marrow Transplant 1998 22 : 935 40.
3. Fruehauf S, Seggewiss R. It's moving day: factors affecting peripheral blood stem cell mobilization and strategies for improvement. Br J Haematol 2003 122 : 360 75.
4. Kessinger A, Sharp JG. The whys and hows of hematopoietic progenitor and stem cell mobilization. Bone Marrow Transplant 2003 31 : 319 29.
5. Haas R, Mohle R, Fruehauf S, et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994 83 : 3787 94.
6. + counts decrease haematological toxicity of autologous peripheral blood progenitor cell transplantation. Blood 1998 91 : 3148 55.
7. + cell dose in blood stem cell transplantation for cancer therapy. J Clin Oncol 2000 18 : 1360 77.
8. + cells ('super mobilizers') have improved survival in autologous stem cell transplantation for lymphoid malignancies. Bone Marrow Transplant 2007 40 : 437 41.
9. Stockerl-Goldstein KE, Reddy SA, Horning SF, et al. Favorable treatment outcome in non-Hodgkin's lymphoma patients with poor mobilization of peripheral blood progenitor cells. Biol Blood Marrow Transplant 2000 6 : 506 12.
10. Wang S, Nademanee A, Qian D, et al. Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantation. Transfusion 2007 47 : 2207 16.
11. To LB, Shepherd KM, Lam-Po-Tang R, et al. Guidelines for the collection, processing, storage and of administration of hemopoietic progenitor cells for transplantation. Pathology 1998 30 : 276 85.
12. Armitage S, Hargreaves R, Samson D, et al. CD34 counts to predict the adequate collection of peripheral blood progenitor cells. Bone Marrow Transplant 1997 20 : 587 91.
13. 2) and granulocyte colony-stimulating factor in patients with multiple myeloma. Bone Marrow Transplant 1996 17 : 691 7.
14. Marit G, Thessard F, Faberes C, et al. Factors affecting both peripheral blood progenitor cell mobilization and hematopoietic recovery following autologous blood progenitor cell transplantation in multiple myeloma patients: a monocentric study. Leukemia 1998 12 : 1447 56.
15. Fitoussi O, Perreau V, Boiron JM, et al. A comparison of toxicity following two different doses of cyclophosphamide for mobilization of peripheral blood progenitor cells in 116 myeloma patients. Bone Marrow Transplant 2001 27 : 837 42.
16. Jantunen E, Putkonen M, Nousiainen T, et al. Low-dose or intermediate-dose cyclophosphamide plus granulocyte colony-stimulating factor for progenitor cell mobilization in patients with multiple myeloma. Bone Marrow Transplant 2003 31 : 347 51.
17. Lerro KA, Medoff E, Wu Y, et al. A simplified approach to stem cell mobilization in multiple myeloma patients not previously treated with alkylating agents. Bone Marrow Transplant 2003 32 : 1113 7.
18. Lefrere F, Zohar S, Ghez D, et al. The VAD chemotherapy regimen plus G-CSF dose of 10 μg/kg is as effective and less toxic than high-dose cyclophosphamide plus a G-CSF dose of 5 μg/kg for progenitor cell mobilization: results from a monocentric study of 82 patients. Bone Marrow Transplant 2006 37 : 725 9.
19. + cells for positive selection in newly diagnosed patients with multiple myeloma. Br J Haematol 1996 92 : 263 8.
20. Koc ON, Gerson SL, Cooper BW, et al. Randomized cross-over trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony stimulating factor plus G-CSF. J Clin Oncol 2000 18 : 1824 30.
21. Dingli D, Nowakowski GS, Dispenzieri A, et al. Cyclophosphamide mobilization does not improve outcome in patients receiving stem cell transplantation for multiple myeloma. Clin Lymphoma Myeloma 2006 6 : 384 8.
22. Hosing C, Qazilbash MH, Kebriaei P, et al. Fixed-dose single agent pegfilgrastim for peripheral blood progenitor cell mobilization in patients with multiple myeloma. Br J Haematol 2006 133 : 533 7.
23. 2) supported by autologous stem cell transplantation is safe and effective in elderly (≥ 65 years) myeloma patients: comparison with younger patients treated on the same protocol. Bone Marrow Transplant 2006 37 : 917 22.
24. + cells in patients with multiple myeloma. Haematologica 2006 91 : 621 7.
25. Ghobrial IM, Dispenzieri A, Bundy KL, et al. Effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma. Bone Marrow Transplant 2003 32 : 587 92.
26. Cavo M, Zamagni E, Tosi P, et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005 106 : 35 9.
27. Breitkreutz I, Lokhorst HM, Raab MS, et al. Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield. Leukemia 2007 21 : 1294 9.
28. Jagannath S, Durie BG, Wolf J, et al. Bortezomid therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 2005 129 : 776 83.
29. Harousseau JL, Attal M, Leleu X, et al. Bortezomib plus deamethasone as induction treatment in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica 2006 91 : 1498 505.
30. Oakervee HE, Popat R, Curry N, et al. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol 2005 129 : 755 62.
31. Perry AR, Watts MJ, Peniket AJ, et al. Progenitor cell yields are frequently poor in patients with histologically indolent lymphomas especially when mobilized within 6 months of previous chemotherapy. Bone Marrow Transplant 1998 21 : 1201 5.
32. Sugrue MW, Williams K, Pollock BH, et al. Characterization and outcome of "hard to mobilize" lymphoma patients undergoing autologous stem cell transplantation. Leuk Lymphoma 2000 39 : 509 19.
33. Kuittinen T, Nousiainen T, Halonen P, et al. Prediction of mobilisation failure in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 2004 33 : 907 12.
34. Ketterer N, Salles G, Moullet I, et al. Factors associated with successful mobilization of peripheral blood progenitor cells in 200 patients with lymphoid malignancies. Br J Haematol 1998 103 : 235 42.
35. Laszlo D, Galieni P, Raspadori D, et al. Fludarabine containing-regimens may adversely affect peripheral blood stem cell collection in low-grade lymphoma patients. Leuk Lymphoma 2000 37 : 157 61.
36. Drake M, Ranaghan L, Morris TC, et al. Analysis of effect of prior therapy on progenitor cell yield: use of a chemotherapy scoring system. Br J Haematol 1997 98 : 745 9.
37. Jantunen E, Kuittinen T, Nousiainen T. Is chemotherapy scoring useful to predict progenitor cell mobilisation in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 2003 32 : 569 73.
38. st line treatment of peripheral T-cell lymphomas (PTCL) - A phase II study of the Nordic Lymphoma Group. Blood 2006 108 : 123a. (abstract).
39. Geisler C, Elonen E, Kolsad A, et al. Nordic Mantle Cell Lymphoma (MCL) Project: prolonged follow-up of 86 patients treated with BEAM/BEAC + PBSCT confirm that addition of high-dose AraC and rituximab increases clinical and molecular response rates, PCR-negative grafts, failure-free survival, relapse-free survival and overall survival. Blood 2004 105 : 6a. (abstract).
40. Moskowitz CH, Bertino JR, Glassman JR, et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol 1999 17 : 3776 85.
41. Herzberg MS, Crombie C, Benson W, et al. Outpatient-based ifosfamide, carboplatin, and etopside (ICE) chemotherapy in transplant-eligible patients with non-Hodgkin's lymphoma and Hodgkin's disease. Ann Oncol 2003 14 (Suppl 1 11 6.
42. Kewalramani T, Zelenetz AD, Nimer SD, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2004 103 : 3684 8.
43. Jerkeman M, Leppä S, Kvaloy S, Holte H. ICE (ifosfamide, carboplatin, etoposide) as a second-line chemotherapy in relapsed or primary progressive aggressive lymphoma - The Nordic Lymphoma Group experience. Eur J Haematol 2004 73 : 179 82.
44. Pavone V, Gaudio F, Guarini A, et al. Mobilization of peripheral blood stem cells with high-dose cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin's lymphoma. Bone Marrow Transplant 2002 29 : 285 90.
45. Olivieri A, Brunoli M, Capelli D, et al. Salvage therapy with an outpatient DHAP schedule followed by PBSC transplantation in 79 lymphoma patients: an intention to mobilize and transplant analysis. Eur J Haematol 2004 72 : 10 7.
46. Aurlien E, Holte H, Pharo A, et al. Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBSC in patients with Hodgkin's and non-Hodgkin's lymphoma. Bone Marrow Transplant 1998 21 : 873 8.
47. Akhtar S, Tbakhi A, Humaidan H, et al. ESHAP + fixed dose G-CSF as autologous peripheral blood stem cell mobilization regimen in patients with relapsed or refractory diffuse large cell and Hodgkin's lymphoma: a single institution result in 127 patients. Bone Marrow Transplant 2006 37 : 277 82.
48. Bishton MJ, Lush RJ, Byrne JL, et al. Ifosfamide, etoposide and epirubicin is an effective combined salvage and peripheral blood stem cell mobilization regimen for transplant-eligible patients with non-Hodgkin lymphoma and Hodgkin disease. Br J Haematol 2007 136 : 752 61.
49. Reiser M, Josting A, Draube A, et al. Successful peripheral blood stem cell mobilization with etoposide (VP-16) in patients with relapsed or resistant lymphoma who failed cyclophosphamide mobilization. Bone Marrow Transplant 1999 23 : 1223 8.
50. Corazzelli G, Russo F, Capobianco G, et al. Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study. Ann Oncol 2006 17 (Suppl 4 18 24.
51. Jantunen E, Leppä S, Kuittinen T, et al. Cyclophoshamide or disease-specific chemotherapy for progenitor cell mobilisation in patients with relapsed diffuse large B-cell lymphoma? Bone Marrow Transplant 2007 39 (Suppl 1 S152. (abstract).
52. Benekli M, Hahn T, Shafi F, et al. Effect of rituximab on peripheral blood stem cell mobilization and engraftment kinetics in non-Hodgkin's lymphoma patients. Bone Marrow Transplant 2003 32 : 139 43.
53. Endo T, Sato N, Mogi Y, et al. Peripheral blood stem cell mobilization following CHOP plus rituximab therapy combined with G-CSF in patients with B-cell non-Hodgkin's lymphoma. Bone Marrow Transplant 2004 33 : 703 7.
54. Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed or resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993 341 : 1051 4.
55. Schmitz N, Pfistner B, Sextro M, et al. for German Hodgkin's Lymphoma Study Group and Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomized trial. Lancet 2002 359 : 2065 71.
56. Smardova L, Engert A, Haverkamp H, et al. Successful mobilization of peripheral blood stem cells with the DHAP-regimen (dexamethasone, cytarabine, cislatin) plus granulocyte colony-stimulating factor in patients with relapsed Hodgkin's disease. Leuk Lymphoma 2005 46 : 1017 22.
57. Kuruvilla J, Nagy T, Pintilie M, et al. Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma. Cancer 2006 106 : 353 60.
58. Milligan DW, Fernandes S, Dasgupta R, et al. Results of the MRC pilot study show autografting for younger patients is safe and achieves a high percentage of molecular responses. Blood 2005 105 : 397 404.
59. Tournilhac O, Gazin B, Leprerre S, et al. Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia. Blood 2004 103 : 363 5.
60. Eichhorst BF, Busch R, Hopfinger G, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first line therapy in younger patients with chronic lymphocytic leukemia. Blood 2006 107 : 885 91.
61. Jantunen E, Itälä M, Siitonen T, et al. Progenitor cell mobilisation and collection in patients with chronic lymphocytic leukaemia: a nation-wide analysis. Bone Marrow Transplant 2007, Oct 29 (e-pub ahead of print).
62. Scime R, Indovina A, Santoro A, et al. PBSC mobilization, collection and positive selection in patients with chronic lymphocytic leukaemia. Bone Marrow Transplant 1998 22 : 1159 65.
63. + cell mobilization by intermediate-dose AraC in chronic lymphocytic leukemia patients treated with sequential fludarabine and Campath-1H. Leukemia 2004 18 : 57 62.
64. Sutton L, Genet P, Tournilhac O, et al. PBSC mobilization in CLL patients: impact of previous treatment with fludarabine. Bone Marrow Transplant 2007 39 (Suppl 1 S7 (O147). (abstract).
65. Jantunen E, Siitonen T, Putkonen M, et al. Autologous stem cell transplantation in patients with primary amyloidosis: a nation-wide survey. Leuk Lymphoma 2004 45 : 2485 589.
66. Saba N, Sutton D, Ross H, et al. High treatment-related mortality in cardiac amyloid patients undergoing autologous stem cell transplant. Bone Marrow Transplant 1999 24 : 53 5.
67. Leung N, Leung TR, Cha SS, et al. Excessive fluid accumulation during stem cell mobilization: a novel prognostic factor of first-year survival after stem cell transplantation in AL amyloidosis patients. Blood 2005 106 : 3353 7.
68. Skinner M, Sanchorawala V, Seldin DC, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004 140 : 85 93.
69. Watts MJ, Sullivan A, Leverett D, et al. Back-up bone marrow is frequently ineffective in patients with poor peripheral-blood stem-cell mobilization. J Clin Oncol 1998 16 : 1554 60.
70. Lemoli RM, de Vivo A, Damiani D, et al. Autologous transplantation of granulocyte colony-stimulating factor-primed bone marrow is effective in supporting myeloablative chemotherapy in patients with hematologic malignancies and poor peripheral blood stem cell mobilization. Blood 2003 102 : 1595 600.
71. Flomenberg N, Devine SM, DiPersio JF, et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF. Blood 2005 106 : 1867 74.
72. + cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant 2007, Nov 12 (e-pub ahead of print).
73. + cells and dendritic cells by AMD3100 plus granulocyte-colony stimulating factor in non-Hodgkin's lymphoma patients. Stem Cells Dev 2007 16 : 657 66.
74. Holtan SG, Porata LF, Micallef IN, et al. AMD3100 affects autograft lymphocyte collection and progression-free survival after autologous stem cell transplantation in non-Hodgkin's lymphoma. Clin Lymphoma Myeloma 2007 7 : 315 8.